These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31240523)

  • 41. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 43. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
    McCoach CE; Berge EM; Lu X; Barón AE; Camidge DR
    J Thorac Oncol; 2016 Mar; 11(3):407-13. PubMed ID: 26725180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System 
Metastases from Non-small Cell Lung Cancer].
    Jin Y; Xin T
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):496-500. PubMed ID: 27561797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokine immunotherapy of non-small cell lung cancer.
    Dubinett SM; Kradin RL
    Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
    Passiglia F; Commendatore O; Vitali M; Conca R
    Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.
    Limacher JM; Spring-Giusti C; Bellon N; Ancian P; Rooke R; Bonnefoy JY
    Expert Rev Vaccines; 2013 Mar; 12(3):263-70. PubMed ID: 23496666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment options after first-line immunotherapy in metastatic NSCLC.
    Santos ES
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):221-228. PubMed ID: 32141356
    [No Abstract]   [Full Text] [Related]  

  • 53. [Vaccines for the treatment of non-small cell lung cancer].
    Leduc C; Quoix E
    Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
    Yao S; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Ahluwalia MS; Becker K; Levy BP
    Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 58. Immune-based Therapies for Non-small Cell Lung Cancer.
    Rafei H; El-Bahesh E; Finianos A; Nassereddine S; Tabbara I
    Anticancer Res; 2017 Feb; 37(2):377-387. PubMed ID: 28179283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
    Kelly RJ; Gulley JL; Giaccone G
    Clin Lung Cancer; 2010 Jul; 11(4):228-37. PubMed ID: 20630824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.